Literature DB >> 11060328

New therapeutic agents targeting the epidermal growth factor receptor.

J Baselga1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11060328

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Prospect of anticancer therapy.

Authors:  Hee-Sook Park
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

2.  Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.

Authors:  Katharina Kuester; Andreas Kovar; Christian Lüpfert; Brigitte Brockhaus; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  An update on epidermal growth factor receptor inhibitors.

Authors:  Shanu Modi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

4.  Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Authors:  Alessandro D Santin; Michael W Sill; D Scott McMeekin; Mario M Leitao; Jubilee Brown; Gregory P Sutton; Linda Van Le; Patricia Griffin; Cecelia H Boardman
Journal:  Gynecol Oncol       Date:  2011-09       Impact factor: 5.482

Review 5.  Targeting epidermal growth factor receptor in lung cancer.

Authors:  José Baselga; Joan Albanell
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

6.  Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.

Authors:  Regine Choe; Turgut Durduran
Journal:  IEEE J Sel Top Quantum Electron       Date:  2011-12-02       Impact factor: 4.544

7.  Rational use of cetuximab in the treatment of advanced non-small cell lung cancer.

Authors:  Charu Aggarwal; Hossein Borghaei
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

8.  Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis.

Authors:  Ben-Fillippo Krippendorff; Katharina Kuester; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

Review 9.  Molecularly targeted therapy for pediatric brain tumors.

Authors:  Warren K E
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.506

10.  Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption: Three case reports.

Authors:  Szu-Yun Fang; Chieh-Shan Wu; Yi-Shan Liu; Kai-Che Wei
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.